Which has better valuation and earnings, AORT or HAE?

Haemonetics has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.95 $9.77M -$0.07 N/A Haemonetics $1.33B 3.65 $97.31M $2.04 52.44

Is AORT or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to Artivion's net margin of -0.67%. Haemonetics' return on equity of 27.55% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to AORT or HAE?

In the previous week, Haemonetics had 20 more articles in the media than Artivion. MarketBeat recorded 25 mentions for Haemonetics and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat Haemonetics' score of 0.55 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation and earnings, AORT or LIVN?

Artivion has higher earnings, but lower revenue than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.95 $9.77M -$0.07 N/A LivaNova $1.39B 3.14 -$242.47M $3.38 23.39

Is AORT or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% LivaNova 12.82% 16.35% 7.76%

Does the media favor AORT or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Artivion. MarketBeat recorded 6 mentions for LivaNova and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat LivaNova's score of 0.41 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AORT or ITGR?

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.95 $9.77M -$0.07 N/A Integer $1.84B 2.31 $102.81M $3.66 34.25

Is AORT or ITGR more profitable?

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% Integer 6.97% 12.79% 6.48%

Does the media favor AORT or ITGR?

In the previous week, Integer had 15 more articles in the media than Artivion. MarketBeat recorded 20 mentions for Integer and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat Integer's score of 0.43 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AORT or IRTC?

In the previous week, Artivion had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Artivion and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.75 beat Artivion's score of 1.08 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AORT or PLSE?

In the previous week, Artivion had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Artivion and 4 mentions for Pulse Biosciences. Artivion's average media sentiment score of 1.08 beat Pulse Biosciences' score of 0.61 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Artivion (AORT) Competitors

$26.83 +0.45 (+1.71%)

As of 02:46 PM Eastern

Compare

AORT vs. HAE, LIVN, ITGR, IRTC, and PLSE

Should you buy Artivion stock or one of its competitors? Artivion's main competitors and comparable companies include Haemonetics (HAE), LivaNova (LIVN), Integer (ITGR), iRhythm Technologies (IRTC), and Pulse Biosciences (PLSE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Artivion compare to Haemonetics?

Artivion (NYSE:AORT) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Artivion presently has a consensus price target of $44.83, indicating a potential upside of 67.83%. Haemonetics has a consensus price target of $97.56, indicating a potential downside of 8.81%. Given Artivion's stronger consensus rating and higher probable upside, equities research analysts plainly believe Artivion is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Artivion has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Haemonetics had 20 more articles in the media than Artivion. MarketBeat recorded 25 mentions for Haemonetics and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat Haemonetics' score of 0.55 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Haemonetics has a net margin of 7.12% compared to Artivion's net margin of -0.67%. Haemonetics' return on equity of 27.55% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Haemonetics	7.12%	27.55%	9.65%

86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Haemonetics has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.95	$9.77M	-$0.07	N/A
Haemonetics	$1.33B	3.65	$97.31M	$2.04	52.44

Summary

Haemonetics beats Artivion on 11 of the 17 factors compared between the two stocks.

How does Artivion compare to LivaNova?

Artivion (NYSE:AORT) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Artivion has higher earnings, but lower revenue than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.95	$9.77M	-$0.07	N/A
LivaNova	$1.39B	3.14	-$242.47M	$3.38	23.39

Artivion has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Artivion presently has a consensus price target of $44.83, indicating a potential upside of 67.83%. LivaNova has a consensus price target of $83.50, indicating a potential upside of 5.61%. Given Artivion's stronger consensus rating and higher possible upside, research analysts clearly believe Artivion is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, LivaNova had 1 more articles in the media than Artivion. MarketBeat recorded 6 mentions for LivaNova and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat LivaNova's score of 0.41 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
LivaNova	12.82%	16.35%	7.76%

86.4% of Artivion shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 6.3% of Artivion shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

LivaNova beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to Integer?

Artivion (NYSE:AORT) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.95	$9.77M	-$0.07	N/A
Integer	$1.84B	2.31	$102.81M	$3.66	34.25

86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Integer	6.97%	12.79%	6.48%

Artivion presently has a consensus target price of $44.83, suggesting a potential upside of 67.83%. Integer has a consensus target price of $109.86, suggesting a potential downside of 12.37%. Given Artivion's stronger consensus rating and higher possible upside, research analysts clearly believe Artivion is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Artivion has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, Integer had 15 more articles in the media than Artivion. MarketBeat recorded 20 mentions for Integer and 5 mentions for Artivion. Artivion's average media sentiment score of 1.08 beat Integer's score of 0.43 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Integer beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Artivion had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Artivion and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.75 beat Artivion's score of 1.08 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Artivion has higher earnings, but lower revenue than iRhythm Technologies. Artivion is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.95	$9.77M	-$0.07	N/A
iRhythm Technologies	$747.14M	5.20	-$44.55M	-$0.43	N/A

Artivion has a net margin of -0.67% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
iRhythm Technologies	-1.69%	10.11%	1.53%

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Artivion has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Artivion currently has a consensus target price of $44.83, indicating a potential upside of 67.83%. iRhythm Technologies has a consensus target price of $179.93, indicating a potential upside of 52.51%. Given Artivion's higher possible upside, analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

iRhythm Technologies beats Artivion on 9 of the 17 factors compared between the two stocks.

How does Artivion compare to Pulse Biosciences?

Artivion (NYSE:AORT) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

86.4% of Artivion shares are held by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artivion has higher revenue and earnings than Pulse Biosciences. Artivion is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.95	$9.77M	-$0.07	N/A
Pulse Biosciences	$1.19M	2,849.64	-$72.78M	-$1.18	N/A

In the previous week, Artivion had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Artivion and 4 mentions for Pulse Biosciences. Artivion's average media sentiment score of 1.08 beat Pulse Biosciences' score of 0.61 indicating that Artivion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has a net margin of -0.67% compared to Pulse Biosciences' net margin of -6,755.78%. Artivion's return on equity of 6.07% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Artivion presently has a consensus price target of $44.83, suggesting a potential upside of 67.83%. Pulse Biosciences has a consensus price target of $45.25, suggesting a potential downside of 7.26%. Given Artivion's stronger consensus rating and higher possible upside, equities analysts plainly believe Artivion is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Artivion has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Summary

Artivion beats Pulse Biosciences on 12 of the 16 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.30B	$5.80B	$7.30B	$24.28B
Dividend Yield	N/A	1.74%	2.53%	3.70%
P/E Ratio	-381.57	26.23	272.80	30.26
Price / Sales	2.95	44.69	626.81	20.12
Price / Cash	24.41	33.27	78.57	32.63
Price / Book	2.92	6.23	13.14	7.71
Net Income	$9.77M	$149.10M	$3.47B	$1.07B
7 Day Performance	-7.56%	0.22%	1.22%	-0.18%
1 Month Performance	5.51%	9.17%	8.61%	2.90%
1 Year Performance	-39.24%	6.87%	26.08%	14.64%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	3.9867 of 5 stars	$26.79 +1.6%	$44.83 +67.4%	-39.5%	$1.31B	$441.33M	N/A	1,800
HAE Haemonetics	2.7084 of 5 stars	$108.34 -0.4%	$97.56 -10.0%	+95.9%	$4.95B	$1.35B	53.11	3,009	Trending News Analyst Revision
LIVN LivaNova	2.6561 of 5 stars	$78.26 -0.6%	$83.50 +6.7%	+40.9%	$4.34B	$1.39B	23.15	3,300
ITGR Integer	2.7491 of 5 stars	$124.90 -0.2%	$109.86 -12.0%	+15.1%	$4.26B	$1.85B	34.12	11,000	Trending News Analyst Revision
IRTC iRhythm Technologies	4.3404 of 5 stars	$125.25 -2.5%	$179.93 +43.7%	-25.7%	$4.24B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. HAE, LIVN, ITGR, IRTC, and PLSE

How does Artivion compare to Haemonetics?

Summary

How does Artivion compare to LivaNova?

Summary

How does Artivion compare to Integer?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

How does Artivion compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. HAE, LIVN, ITGR, IRTC, and PLSE

How does Artivion compare to Haemonetics?

Do analysts rate AORT or HAE?

Which has more volatility and risk, AORT or HAE?

Does the media refer more to AORT or HAE?

Is AORT or HAE more profitable?

Do insiders and institutionals hold more shares of AORT or HAE?

Which has better valuation and earnings, AORT or HAE?

Summary

How does Artivion compare to LivaNova?

Which has higher valuation and earnings, AORT or LIVN?

Which has more risk & volatility, AORT or LIVN?

Do analysts prefer AORT or LIVN?

Does the media favor AORT or LIVN?

Is AORT or LIVN more profitable?

Do institutionals and insiders hold more shares of AORT or LIVN?

Summary

How does Artivion compare to Integer?

Which has preferable earnings and valuation, AORT or ITGR?

Do institutionals & insiders hold more shares of AORT or ITGR?

Is AORT or ITGR more profitable?

Do analysts recommend AORT or ITGR?

Which has more risk & volatility, AORT or ITGR?

Does the media favor AORT or ITGR?

Summary

How does Artivion compare to iRhythm Technologies?

Does the media favor AORT or IRTC?

Which has stronger earnings and valuation, AORT or IRTC?

Is AORT or IRTC more profitable?

Do institutionals and insiders believe in AORT or IRTC?

Which has more risk and volatility, AORT or IRTC?

Do analysts recommend AORT or IRTC?

Summary

How does Artivion compare to Pulse Biosciences?

Do insiders & institutionals hold more shares of AORT or PLSE?

Which has higher valuation & earnings, AORT or PLSE?

Does the media refer more to AORT or PLSE?

Is AORT or PLSE more profitable?

Do analysts recommend AORT or PLSE?

Which has more risk & volatility, AORT or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools